Actualités et vidéos - THERMO FISHER SCIENTIFIC INC

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. (EST). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with...

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, January 30, 2025, and will hold a conference call on the same day at 8:30 a.m. EST. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is...

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the repurchase of $1 billion (1.9 million shares) of its common stock. As of December 3, 2024, $3 billion remained available under the company’s share repurchase authorization. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the...

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date. This replaces the company’s existing repurchase authorization, of which $1 billion was remaining. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with...

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Wolfe Healthcare Conference on Tuesday, November 19, 2024 at 8:00 a.m. (EDT). You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over...

Thermo Fisher Scientific, National University Hospital and Mirxes Collaborate to Enhance Access to Advanced Genomic Testing for Early Cancer Detection in Singapore PR Newswire SINGAPORE, June 18, 2024 Partnership Aims to Personalize Cancer Care Tailored to the Needs of Southeast Asian Population to Provide Better Individualized Care SINGAPORE , June 18, 2024 /PRNewswire/ -- To increase patient access to affordable, advanced genomic testing for cancer in Singapore , Thermo Fisher Scientific Inc.,...

BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH THERMO FISHER SCIENTIFIC PR Newswire MINNEAPOLIS, April 29, 2024 MINNEAPOLIS , April 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities is pleased to announce a significant milestone in its commitment to providing cutting-edge solutions to its customers. Effective May 1, 2024 , Bio-Techne will enter...

Thermo Fisher Scientific unterzeichnet langfristigen, exklusiven US-Vertriebsvertrag mit Aesku.Group für IFA-Testkits und -Instrumente PR Newswire WENDELSHEIM, Deutschland, 13. Dezember 2023 ­­ Kernbotschaften Thermo Fisher Scientific wurde zum exklusiven Vertriebshändler für FDA-zugelassene Aesku-Produkte in den Vereinigten Staaten ernannt. Thermo Fisher Scientific ist ein führender Anbieter von Instrumenten und Verbrauchsmaterialien für den Spezialdiagnostikmarkt, dessen Portfolio an...

EDX MEDICAL ANNOUNCES COLLABORATION WITH THERMO FISHER SCIENTIFIC TO DEVELOP INNOVATIVE CANCER TESTS FOR GLOBAL HEALTHCARE MARKETS PR Newswire CAMBRIDGE, England, Nov. 21, 2023 CAMBRIDGE, England , Nov. 21, 2023 /PRNewswire/ -- EDX Medical Group ("EDX Medical"), a developer of innovative digital diagnostic products and services for personalised treatment of cancer, heart disease and infectious diseases, today announced it has entered into a collaborative agreement with Thermo Fisher Scientific...

Devyser and Thermo Fisher Scientific collaborate to promote laboratory services to advance pharmaceutical research PR Newswire STOCKHOLM, Sept. 13, 2023 STOCKHOLM , Sept. 13, 2023 /PRNewswire/ -- Devyser and Thermo Fisher Scientific have entered into a collaboration agreement to promote laboratory services. The goal is to partner with pharmaceutical companies to support their development projects utilising Devyser's unique assays in its CLIA-certified laboratory. The companies will work together...

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has completed the acquisition of CorEvitas, LLC (“CorEvitas”), a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity (“Audax”), for $912.5 million in cash. Thermo Fisher announced the agreement to acquire CorEvitas on July 6, 2023 . Real-world evidence is the collection and use of...

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $2.95 billion aggregate principal amount (the “Offering”) of the following notes, each issued at par: $600 million aggregate principal amount of its 4.953% senior notes due 2026 (the “2026 notes”); $750 million aggregate principal amount of its 4.977% senior notes due 2030 (the “2030 notes”); $1 billion aggregate principal amount of its 5.086% senior notes due 2033 (the...

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 1, 2023. Second Quarter 2023 Highlights Second quarter revenue was $10.69 billion, 3% lower versus the same quarter last year. Core organic revenue growth was 2%. Second quarter GAAP diluted earnings per share (EPS) was $3.51. Second quarter adjusted EPS was $5.15. The macroeconomic environment was more challenging in the second quarter and our...

Thermo Fisher Scientific Inc, leader mondial au service de la science, a annoncé aujourd'hui que la société a rejoint les Jeux Olympiques et Paralympiques de Paris 2024 en tant que Supporteur Officiel, fournissant des instruments analytiques, des équipements de laboratoire et une expertise pour identifier l'usage abusif de substances et méthodes interdites par l'Agence mondiale antidopage (AMA) afin de contribuer à une compétition propre et de maintenir l'intégrité sportive lors du plus...

To extend the benefits of genomic testing research for reproductive health labs, Thermo Fisher Scientific today launched two new next-generation sequencing-based options to support preimplantation genetic testing-aneuploidy (PGT-A) used commonly to inform in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research. The Ion ReproSeq PGT-A Kit * and the Ion AmpliSeq Polyploidy Kit * mark the first research use reproductive health assays available on the Ion Torrent Genexus...

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.35 per common share, payable on October 13, 2023, to shareholders of record as of September 15, 2023. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer....

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced Jenny Johnson, president and chief executive officer of Franklin Resources, Inc. (NYSE:BEN), has been elected to its board of directors. The appointment brings the total number of Thermo Fisher board members to 12. In a career at Franklin Templeton spanning 35 years, Johnson has been a key driver in the company's transformation to what is now one of the largest global asset managers with over $1.4...

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced it has entered into a definitive agreement to acquire CorEvitas, LLC (“CorEvitas”), a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity (“Audax”), for $912.5 million in cash. Real-world evidence is the collection and use of patient health outcomes data gathered through routine clinical care....

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2023 before the market opens on Wednesday, July 26, 2023, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 852304. You may...

Thermo Fisher Scientific, leader mondial au service de la science, a annoncé aujourd'hui le lancement du kit Gibco™ OncoPro™ Tumoroid Culture Medium *, le premier milieu de culture disponible dans le commerce spécifiquement développé pour l'expansion de tumoroïdes provenant de patients, ou d'organoïdes cancéreux, à partir de multiples types de cancer. Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici :...